N/A N=69 MOWI Research Pilot
Obesity
Primary: Change in Grip Strength — 6.2; -2.6; 4.3 Kg
Clinical Trial Search
Completed trials with posted results — search by concept, filter by the parameters that matter at the bedside.
Phase 2 N=60 Oral Enzastaurin in Participants With Relapsed Mantle Cell Lymphoma
Mantle-Cell Lymphoma
Primary: Percentage of Participants With Freedom From Progression (FFP) for at Least 3 Cycles — 35.6 percentage of participants
Phase 3 N=34 Metformin for the Prevention of Episodic Migraine (MPEM)
Migraine
Primary: Headache Days — 23.64; 24.33 Days — p=0.83
Phase 4 N=16 HIV Persistence and Viral Reservoirs
HIV · HIV Infections
Primary: Mean Change in Estimated Ultrasensitive Plasma HIV RNA Levels Between Baseline and Week 24 — 66 fold decrease in signal/cutoff ratio
Phase 3 N=109 Study of Eteplirsen in DMD Patients
Duchenne Muscular Dystrophy (DMD)
Primary: Change From Baseline in the 6 Minute Walk Test (6MWT) Distance at Week 96 — -117.91; -133.56 meters
Phase 2 N=12 Ixekizumab in the Treatment of Pityriasis Rubra Pilaris (PRP)
Pityriasis Rubra Pilaris
Primary: Clinical Improvement in PRP Severity and Body Surface Area — 15.2 units on a scale — p=<0.001
Phase 1 N=98 4-Week, Multiple-dose, Dose-escalating Study In Patients With Type 2 Diabetes
Type 2 Diabetes Mellitus
Primary: Number of Participants With All-causality and Treatment-related Treatment-emergent Adverse Events (TEAEs) — 17; 6; 8; 10 Participants
N/A N=129 Contacting Authors to Retrieve Individual Patient Data
Response Rates
Primary: Proportion of Authors Who Provided Complete IPD — 0; 0 Participants
Phase 2 N=50 Efficacy and Safety of a 0.1% Tacrolimus Nasal Ointment as a Treatment for Epistaxis in Hemorrhagic Hereditary Telangiectasia (HHT)
Hemorrhagic Hereditary Telangiectasia (HHT)
Primary: Percentage of Patients Experiencing an Improvement in Their Nosebleeds — 10; 9 Participants — p=<0.05
Phase 1 N=13 A Drug Interaction Study to Assess the Effect of LY317615 on the Metabolic Pathway of Warfarin
Solid Tumor · Lymphoma, Malignant
Primary: Pharmacokinetics: Maximum Plasma Concentration (Cmax) of S-Warfarin and R-Warfarin — 245; 198; 253; 230 nanograms/milliliter (ng/mL)
N/A N=30 The EvAluation of TaBlo In-CLinic and In-HOme
End Stage Renal Disease
Primary: Weekly Standardized Dialysis Adequacy — 2.8; 2.8 Weekly Standardized Kt/V
Phase 2 N=54 Efficacy and Safety of Simtuzumab in Adults With Primary, Post Polycythemia Vera or Post Essential Thrombocythemia Myelofibrosis
Myelofibrosis
Primary: Rate of Clinical Response as Defined by the Percentage of Participants With Reduction at Week 24 From Baseline in the Bone Marrow Fibrosis Score — 0; 16.7; 6.7; 13.3…
Phase 2 N=85 AMG 386 Phase 2 Open-Label Renal Cell Carcinoma (RCC) Study 1st Line or After Cytokine Failure in Combination With Sunitinib
Advanced Renal Cell Carcinoma
Primary: Number of Participants With Treatment-Emergent Adverse Events (TEAEs), Serious Adverse Events (SAEs), and Discontinuations (DCs) Due to Adverse Events (AEs) — 43; 42…
Phase 2 N=27 Safety and Efficacy of rAAV-hRS1 in Patients With X-linked Retinoschisis (XLRS)
X-linked Retinoschisis
Primary: Number of Participants Experiencing Adverse Events — 6; 7; 12 Participants
N/A N=21 Depression, Obesity and Inflammatory Markers
Bipolar Disorder · Depression · Obesity
Primary: Change in Depression as Measured by the Hamilton Depression Scale Collected at Baseline and Week 8 — -12.2; -12.0 units on a scale — p=<0.05